An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Naoki Hoshino; Masanobu Yanase; Taisuke Ichiyasu; Kazuhiko Kuwahara; Hideki Kawai; Takashi Muramatsu; Hideki Ishii; Tetsuya Tsukamoto; Shin ichiro Morimoto; Hideo Izawa

doi:10.1016/j.jccase.2022.06.006

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Naoki Hoshino
, Masanobu Yanase
, Taisuke Ichiyasu
, Kazuhiko Kuwahara
, Hideki Kawai
, Takashi Muramatsu
, Hideki Ishii
, Tetsuya Tsukamoto
, Shin ichiro Morimoto
, Hideo Izawa

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

Original language	English
Pages (from-to)	391-394
Number of pages	4
Journal	Journal of Cardiology Cases
Volume	26
Issue number	6
DOIs	https://doi.org/10.1016/j.jccase.2022.06.006
Publication status	Published - 12-2022
Externally published	Yes

All Science Journal Classification (ASJC) codes

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jccase.2022.06.006

Cite this

@article{14d4e01f76bb404baa71b8ad5f39a5e7,

title = "An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination",

abstract = "There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.",

keywords = "Autopsy, Coronavirus disease 2019, Eosinophilic myocarditis, Myocarditis, Vaccination, mRNA",

author = "Naoki Hoshino and Masanobu Yanase and Taisuke Ichiyasu and Kazuhiko Kuwahara and Hideki Kawai and Takashi Muramatsu and Hideki Ishii and Tetsuya Tsukamoto and Morimoto, \{Shin ichiro\} and Hideo Izawa",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Ltd",

year = "2022",

month = dec,

doi = "10.1016/j.jccase.2022.06.006",

language = "English",

volume = "26",

pages = "391--394",

journal = "Journal of Cardiology Cases",

issn = "1878-5409",

publisher = "Elsevier Ltd",

number = "6",

}

TY - JOUR

T1 - An autopsy case report of fulminant myocarditis

T2 - Following mRNA COVID-19 vaccination

AU - Hoshino, Naoki

AU - Yanase, Masanobu

AU - Ichiyasu, Taisuke

AU - Kuwahara, Kazuhiko

AU - Kawai, Hideki

AU - Muramatsu, Takashi

AU - Ishii, Hideki

AU - Tsukamoto, Tetsuya

AU - Morimoto, Shin ichiro

AU - Izawa, Hideo

PY - 2022/12

Y1 - 2022/12

N2 - There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

AB - There have been few case reports on fatal outcomes in patients with acute myocarditis after mRNA coronavirus disease 2019 (COVID-19) vaccination. In most cases of myocarditis after mRNA COVID-19 vaccination, the myocarditis is mild, and the prognosis is good. Here we report an autopsy case of fulminant myocarditis following mRNA COVID-19 vaccination. Learning objective: The global distribution of the mRNA coronavirus disease 2019 vaccine requires consideration of appropriate treatment for postvaccination myocarditis. Eosinophil-mediated immunological injury to cardiomyocytes can be involved in the cause of fulminant inflammation from the pathological findings of postvaccination myocarditis.

KW - Autopsy

KW - Coronavirus disease 2019

KW - Eosinophilic myocarditis

KW - Myocarditis

KW - Vaccination

KW - mRNA

UR - https://www.scopus.com/pages/publications/85134796480

UR - https://www.scopus.com/pages/publications/85134796480#tab=citedBy

U2 - 10.1016/j.jccase.2022.06.006

DO - 10.1016/j.jccase.2022.06.006

M3 - Article

AN - SCOPUS:85134796480

SN - 1878-5409

VL - 26

SP - 391

EP - 394

JO - Journal of Cardiology Cases

JF - Journal of Cardiology Cases

IS - 6

ER -

An autopsy case report of fulminant myocarditis: Following mRNA COVID-19 vaccination

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this